SEC 13F Intelligence

Opaleye Management Inc. / TCE2

Opaleye Management Inc.’s Celldex Therapeutics Inc New Position

Does Opaleye Management Inc. own Celldex Therapeutics Inc New (TCE2)? Not currently — the last reported position was 90.0K shares worth $2M in Q2 2022; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$2M
Q2 2022
Shares
90.0K
% of Portfolio
+1.09%
Quarters Held
9
position exited

Position History TCE2

Reported value by quarter
Q2 ’20: $14MQ2 ’20Q3 ’20: $15MQ4 ’20: $17MQ4 ’20Q1 ’21: $20MQ2 ’21: $33MQ2 ’21Q3 ’21: $53MQ4 ’21: $33MQ4 ’21Q1 ’22: $7MQ2 ’22: $2MQ2 ’22filingsflow.com
QuarterSharesValue% of Portfolio
Q2 202290.0K$2M+1.09%
Q1 2022195.5K$7M+2.07%
Q4 2021844.0K$33M+6.92%
Q3 2021985.0K$53M+9.91%
Q2 2021985.0K$33M+5.47%
Q1 2021985.0K$20M+2.98%
Q4 2020992.0K$17M+2.27%
Q3 2020992.0K$15M+2.88%
Q2 20201.07M$14M+2.81%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Opaleye Management Inc.’s full portfolio or all institutional holders of TCE2.